A key challenge to pediatric medication use is that not all drugs have been tested in this population. Which of the following are legislative acts that address this issue by providing more incentive to manufacturers to conduct tests, allowing FDA to take steps to refer drugs for study and requiring manufacturers to conduct tests when it is likely a medication will be used in pediatric patients?
A. The Best Pharmaceuticals for, Children Act (BPCA)
B. The Pediatric Research Equity Act (PREA)
C. The Creative Incentives for Pediatric Testing Act (CIPTA)
D. Both A and B